Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Marginally below the dotted line
Mon, 16 Mar 03:30 pm

Indian markets pared losses and showed some strength in the second half of the trading session. BSE-Sensex lost about 20 points while NSE-Nifty has lost about 3 points. S&P BSE Midcap stocks has shown a movement towards moderate losses while S&P BSE Smallcap remained the most out of favour. S&P BSE Midcap and S&P BSE Smallcap lost over 0.3% and 1%, respectively. Commodities pared early gains. Gold price is trading on a flat note with minor losses of 0.10% or Rs 25 at Rs 25,860 levels per 10 grams. However, silver prices continue to show strength. Price per kilogram has increased about 0.60% or Rs 188 and is trading at Rs 35,700 levels. Value of the Indian Rupee against the US Dollar declined by 0.3% or 0.16 and is trading at Rs 62.80 levels.

Investor confidence towards the European markets increased as ECB's bond Purchase Program continue to infuse optimism among investors. European markets like DAX and FTSE are trading in the green with gains of 0.9% and 0.5%, respectively.

The pharmaceutical sector has advanced moderately in today's trading session. Suven Life Science led from the front with respect to gains. Shares of the company gained over 10% after it received 2 product patents or chemical entities from the US and New Zealand. According to the company the chemical entity is for central nervous system therapy. This therapy has been acquired through an innovative mechanism known as H3 Inverse agonist. There a series of discover made by Suven Life Sciences under the name of H3 ligands. Including these, Suven now has 20 patents approved by the USA and 23 approved by New Zealand.

Power stocks has traded with volatility today. However, shares of Diamond Power gained 20% after the company acquired an order from Assam and Nagaland Government. The order is reported to be worth Rs 3.32 billion. Company said that in last 12 months Diamond Power has received orders worth aggregating to Rs 20.34 billion.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Marginally below the dotted line". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.